Exchange: NASDAQ·Updated 03:59 PM EDT

About ALVR

About

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Berkeley Heights, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
6

Frequently Asked Questions

Advertisement|Remove ads.